tirzepatide psoriatic arthritis Results of the phase 3b TOGETHER-PsA trial showed ixekizumab administered together with in comorbid overweight or obese adults with showed clinically meaningful improvement of psoriatic disease, physical function, weight Combination Therapy Improves Outcomes in

Hur J, Kang JY, Kim YK, Lee SY, Lee HY

B12-containing formulations sometimes produce a mild energy boost that pure tirzepatide does not

The following GLP-1RAs showed a significantly higher odds ratio of discontinuation due to adverse events compared with placebo: lixisenatide (odds ratio 2.86 (95% confidence interval 1.48 to 5.51)), semaglutide (2.61 (1.56 to 4.37)), exenatide (2.39 (1.14 to 4.98)), tirzepatide (2.30 (1.30 to 4.09)), and liraglutide (2.15 (1.26 to 3.69)) (fig 8A)

M., Kaunitz, A

A review of 500 tirzepatide users found approximately 15% reported muscle aches or body pain that they attributed to the medication